Daniel Liebler
Faculty Member
Last active: 2/15/2016

  1. Proteogenomic analysis reveals unanticipated adaptations of colorectal tumor cells to deficiencies in DNA mismatch repair. Halvey PJ, Wang X, Wang J, Bhat AA, Dhawan P, Li M, Zhang B, Liebler DC, Slebos RJ (2014) Cancer Res 74(1): 387-97
    › Primary publication · 24247723 (PubMed) · PMC3896054 (PubMed Central)
  2. Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mertins P, Yang F, Liu T, Mani DR, Petyuk VA, Gillette MA, Clauser KR, Qiao JW, Gritsenko MA, Moore RJ, Levine DA, Townsend R, Erdmann-Gilmore P, Snider JE, Davies SR, Ruggles KV, Fenyo D, Kitchens RT, Li S, Olvera N, Dao F, Rodriguez H, Chan DW, Liebler D, White F, Rodland KD, Mills GB, Smith RD, Paulovich AG, Ellis M, Carr SA (2014) Mol Cell Proteomics 13(7): 1690-704
    › Primary publication · 24719451 (PubMed) · PMC4083109 (PubMed Central)
  3. Alkylation damage by lipid electrophiles targets functional protein systems. Codreanu SG, Ullery JC, Zhu J, Tallman KA, Beavers WN, Porter NA, Marnett LJ, Zhang B, Liebler DC (2014) Mol Cell Proteomics 13(3): 849-59
    › Primary publication · 24429493 (PubMed) · PMC3945913 (PubMed Central)
  4. Targeted quantitation of proteins by mass spectrometry. Liebler DC, Zimmerman LJ (2013) Biochemistry 52(22): 3797-806
    › Primary publication · 23517332 (PubMed) · PMC3674507 (PubMed Central)
  5. Targeted protein capture for analysis of electrophile-protein adducts. Connor RE, Codreanu SG, Marnett LJ, Liebler DC (2013) Methods Mol Biol : 163-76
    › Primary publication · 23475677 (PubMed) · PMC3801415 (PubMed Central)
  6. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. Skates SJ, Gillette MA, LaBaer J, Carr SA, Anderson L, Liebler DC, Ransohoff D, Rifai N, Kondratovich M, Težak Ž, Mansfield E, Oberg AL, Wright I, Barnes G, Gail M, Mesri M, Kinsinger CR, Rodriguez H, Boja ES (2013) J Proteome Res 12(12): 5383-94
    › Primary publication · 24063748 (PubMed) · PMC4039197 (PubMed Central)
  7. Safety assessment of α-amino acids as used in cosmetics. Burnett CL, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA (2013) Int J Toxicol 32(6 Suppl): 41S-64S
    › Primary publication · 24335967 (PubMed)
  8. Safety assessment of triethanolamine and triethanolamine-containing ingredients as used in cosmetics. Fiume MM, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA (2013) Int J Toxicol 32(3 Suppl): 59S-83S
    › Primary publication · 23696578 (PubMed)
  9. Safety assessment of silylates and surface-modified siloxysilicates. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA (2013) Int J Toxicol 32(3 Suppl): 5S-24S
    › Primary publication · 23696579 (PubMed)
  10. Safety assessment of lauriminodipropionic acid, sodium lauriminodipropionate, and disodium lauriminodipropionate as used in cosmetics. Burnett CL, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA (2013) Int J Toxicol 32(5 Suppl): 49S-55S
    › Primary publication · 24174473 (PubMed)